Radiotherapy & Oncology
Volume 96, Issue 1 , Pages 34-37 , July 2010

Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125 monotherapy over 10years

  • Nicholas P. Munro

      Affiliations

    • Department of Urology, St James’s Institute of Oncology, St James’s University Hospital, Leeds, UK
    • Corresponding Author InformationCorresponding author. Address: 48 Franklin road, Harrogate, North Yorkshire, HG1 5EE, UK.
    • ,
  • Bashar Al-Qaisieh

      Affiliations

    • Department of Medical Physics, St James’s Institute of Oncology, St James’s University Hospital, Leeds, UK
    • ,
  • Peter Bownes

      Affiliations

    • Department of Medical Physics, St James’s Institute of Oncology, St James’s University Hospital, Leeds, UK
    • ,
  • Jonathan Smith

      Affiliations

    • Department of Clinical Radiology, St James’s Institute of Oncology, St James’s University Hospital, Leeds, UK
    • ,
  • Brendan Carey

      Affiliations

    • Department of Clinical Radiology, St James’s Institute of Oncology, St James’s University Hospital, Leeds, UK
    • ,
  • David Bottomley

      Affiliations

    • Department of Clinical Oncology, St James’s Institute of Oncology, St James’s University Hospital, Leeds, UK
    • ,
  • Dan Ash

      Affiliations

    • Department of Clinical Oncology, St James’s Institute of Oncology, St James’s University Hospital, Leeds, UK
    • ,
  • Ann M. Henry

      Affiliations

    • Department of Clinical Oncology, St James’s Institute of Oncology, St James’s University Hospital, Leeds, UK

Received 6 February 2009 ,Revised 27 February 2010 ,Accepted 7 March 2010.

References 

  1. Henry AM, Al-Qaisieh B, Gould K, et al. Outcomes following Iodine-125 monotherapy for localized prostate cancer: the results of Leeds ten year single centre brachytherapy experience. Int J Radiat Oncol Biol Phys. 2010;76:50–56
  2. Merrick GS, Galbreath RW, Butler WM, et al. Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer. Cancer. 2007;110:289–296
  3. Potters L, Purrazzella R, Brustein S, et al. The prognostic significance of Gleason Grade in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;56:749–754
  4. Burdick MJ, Reddy CA, Ulchaker J, et al. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer. Int J Radiat Oncol Biol Phys. 2009;73:1439–1445
  5. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement. Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  6. Kuban DA, Levy LB, Potters L, et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;65:1487–1489
  7. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001;166:876–881
  8. Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007;67:327–333
  9. Sylvester JE, Grimm PD, Blasko JC, et al. 15-Year biochemical relapse free survival in clinical Stage T1–T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys. 2007;67:57–64
  10. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  11. Nobes JP, Wells IG, Khaksar SJ, Money-Kyrle JF, Laing RW, Langley SE. Biochemical relapse-free survival in 400 patients treated with I-125 prostate brachytherapy: the Guildford experience. Prostate Cancer Prostatic Dis. 2009;12:61–66
  12. Chan TY, Partin AW, Walsh PC, Epstein JI. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology. 2000;56:823–827
  13. Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2009;75:16–22
  14. Ash D, Al-Qaisieh B, Bottomley D, Carey B, Joseph J. The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer. Radiother Oncol. 2006;79:185–189

PII: S0167-8140(10)00155-6

doi: 10.1016/j.radonc.2010.03.004

Radiotherapy & Oncology
Volume 96, Issue 1 , Pages 34-37 , July 2010

Article Tools

* Image Usage & Resolution